We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > insulin glargine

News List

Biocon, Mylan win patent litigation for Insulin Glargine device patent in the US expresspharma
March 12, 2020
Brings Biocon closer to commercialising Semglee in the US in 2020.
Biocon’s Malaysia Insulin glargine facility receives Certificate of GMP expresspharma
August 23, 2019
The approval expands Biocon’s capacities, with new large scale devices facility coming up to speed to serve growing needs of people with diabetes in EU
UK launch for Mylan, Biocon insulin glargine biosimilar Semglee pharmatimes
November 19, 2018
Mylan and Biocon have announced the UK launch of Semglee - an approved biosimilar of reference medicine insulin glargine.